Anna F Farago1, Martin S Taylor2, Robert C Doebele3, Viola W Zhu4, Shivaani Kummar5, Alexander I Spira6, Theresa A Boyle7, Eric B Haura7, Maria E Arcila8, Ryma Benayed8, Dara L Aisner9, Nora K Horick10, Jochen K Lennerz2, Long P Le2, A John Iafrate2, Sai-Hong I Ou4, Alice T Shaw1, Mari Mino-Kenudson2, Alexander Drilon11. 1. Massachusetts General Hospital Cancer Center, Boston MA. 2. Department of Pathology, Massachusetts General Hospital, Boston MA. 3. Department of Medicine, University of Colorado, Aurora CO. 4. Department of Medicine, University of California, Irvine School of Medicine, Orange CA. 5. Department of Medicine and Radiology, Stanford University, Palo Alto CA. 6. Virginia Cancer Specialists, Fairfax VA. 7. Department of Thoracic Oncology, Moffitt Cancer Center, Tampa FL. 8. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York NY. 9. Department of Pathology, University of Colorado, Aurora CO. 10. Biostatistics Center, Massachusetts General Hospital, Boston MA. 11. Memorial Sloan Kettering Cancer Center, New York NY.
Abstract
Purpose: Gene rearrangements involving NTRK1/2/3 can generate fusion oncoproteins containing the kinase domains of TRKA/B/C, respectively. These fusions are rare in non-small cell lung cancer (NSCLC), with frequency previously estimated to be <1%. Inhibition of TRK signaling has led to dramatic responses across tumor types with NTRK fusions. Despite the potential benefit of identifying these fusions, the clinicopathologic features of NTRK fusion-positive NSCLCs are not well characterized. Methods: We compiled a database of NSCLC cases harboring NTRK fusions. We characterized the clinical, molecular, and histologic features of these cases with central review of histology. Results: We identified 11 NSCLC cases harboring NTRK gene fusions verified by next-generation sequencing (NGS) and with available clinical and pathologic data, forming the study cohort. Fusions involved NTRK1 (7 cases) and NTRK3 (4 cases), with 5 and 2 distinct fusion partners, respectively. Cohort patients were 55% male, with a median age at diagnosis of 47.6 years (range 25.3-86.0) and a median pack year history of 0 (range 0-58). 73% of patients had metastatic disease at diagnosis. No concurrent alterations in KRAS, EGFR, ALK, ROS1, or other known oncogenic drivers were identified. Nine cases were adenocarcinoma, including 2 invasive mucinous adenocarcinomas and 1 adenocarcinoma with neuroendocrine features; one was squamous cell carcinoma; and one was neuroendocrine carcinoma. By collating data on 4872 consecutively screened NSCLC cases from unique patients, we estimate a frequency of NTRK fusions in NSCLC of 0.23% (95% CI 0.11-0.40). Conclusion: NTRK fusions occur in NSCLCs across genders, ages, smoking histories, and histologies. Given the potent clinical activity of TRK inhibitors, we advocate that all NSCLCs be screened for NTRK fusions using a multiplexed NGS-based fusion assay.
Purpose: Gene rearrangements involving NTRK1/2/3 can generate fusion oncoproteins containing the kinase domains of TRKA/B/C, respectively. These fusions are rare in non-small cell lung cancer (NSCLC), with frequency previously estimated to be <1%. Inhibition of TRK signaling has led to dramatic responses across tumor types with NTRK fusions. Despite the potential benefit of identifying these fusions, the clinicopathologic features of NTRK fusion-positive NSCLCs are not well characterized. Methods: We compiled a database of NSCLC cases harboring NTRK fusions. We characterized the clinical, molecular, and histologic features of these cases with central review of histology. Results: We identified 11 NSCLC cases harboring NTRK gene fusions verified by next-generation sequencing (NGS) and with available clinical and pathologic data, forming the study cohort. Fusions involved NTRK1 (7 cases) and NTRK3 (4 cases), with 5 and 2 distinct fusion partners, respectively. Cohort patients were 55% male, with a median age at diagnosis of 47.6 years (range 25.3-86.0) and a median pack year history of 0 (range 0-58). 73% of patients had metastatic disease at diagnosis. No concurrent alterations in KRAS, EGFR, ALK, ROS1, or other known oncogenic drivers were identified. Nine cases were adenocarcinoma, including 2 invasive mucinous adenocarcinomas and 1 adenocarcinoma with neuroendocrine features; one was squamous cell carcinoma; and one was neuroendocrine carcinoma. By collating data on 4872 consecutively screened NSCLC cases from unique patients, we estimate a frequency of NTRK fusions in NSCLC of 0.23% (95% CI 0.11-0.40). Conclusion: NTRK fusions occur in NSCLCs across genders, ages, smoking histories, and histologies. Given the potent clinical activity of TRK inhibitors, we advocate that all NSCLCs be screened for NTRK fusions using a multiplexed NGS-based fusion assay.
Authors: Oliver Gautschi; Julie Milia; Thomas Filleron; Juergen Wolf; David P Carbone; Dwight Owen; Ross Camidge; Vignhesh Narayanan; Robert C Doebele; Benjamin Besse; Jordi Remon-Masip; Pasi A Janne; Mark M Awad; Nir Peled; Chul-Cho Byoung; Daniel D Karp; Michael Van Den Heuvel; Heather A Wakelee; Joel W Neal; Tony S K Mok; James C H Yang; Sai-Hong Ignatius Ou; Georg Pall; Patrizia Froesch; Gérard Zalcman; David R Gandara; Jonathan W Riess; Vamsidhar Velcheti; Kristin Zeidler; Joachim Diebold; Martin Früh; Sebastian Michels; Isabelle Monnet; Sanjay Popat; Rafael Rosell; Niki Karachaliou; Sacha I Rothschild; Jin-Yuan Shih; Arne Warth; Thomas Muley; Florian Cabillic; Julien Mazières; Alexander Drilon Journal: J Clin Oncol Date: 2017-03-13 Impact factor: 44.544
Authors: Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud Journal: Cancer Discov Date: 2017-02-09 Impact factor: 39.397
Authors: Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate Journal: J Clin Oncol Date: 2012-01-03 Impact factor: 44.544
Authors: Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger Journal: J Mol Diagn Date: 2015-03-20 Impact factor: 5.568
Authors: Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger Journal: Nat Med Date: 2017-05-08 Impact factor: 53.440
Authors: A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia Journal: Nat Med Date: 2013-10-27 Impact factor: 53.440
Authors: Anna F Farago; Long P Le; Zongli Zheng; Alona Muzikansky; Alexander Drilon; Manish Patel; Todd M Bauer; Stephen V Liu; Sai-Hong I Ou; David Jackman; Daniel B Costa; Pratik S Multani; Gary G Li; Zachary Hornby; Edna Chow-Maneval; David Luo; Jonathan E Lim; Anthony J Iafrate; Alice T Shaw Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Ryma Benayed; Michael Offin; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Patrice Desmeules; Ryan Ptashkin; Helen Won; Jason Chang; Darragh Halpenny; Alison M Schram; Charles M Rudin; David M Hyman; Maria E Arcila; Michael F Berger; Ahmet Zehir; Mark G Kris; Alexander Drilon; Marc Ladanyi Journal: Clin Cancer Res Date: 2019-04-26 Impact factor: 12.531
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Alexander Drilon; Salvatore Siena; Rafal Dziadziuszko; Fabrice Barlesi; Matthew G Krebs; Alice T Shaw; Filippo de Braud; Christian Rolfo; Myung-Ju Ahn; Jürgen Wolf; Takashi Seto; Byoung Chul Cho; Manish R Patel; Chao-Hua Chiu; Thomas John; Koichi Goto; Christos S Karapetis; Hendrick-Tobias Arkenau; Sang-We Kim; Yuichiro Ohe; Yu-Chung Li; Young K Chae; Christine H Chung; Gregory A Otterson; Haruyasu Murakami; Chia-Chi Lin; Daniel S W Tan; Hans Prenen; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; Robert C Doebele Journal: Lancet Oncol Date: 2019-12-11 Impact factor: 41.316
Authors: B Melosky; N Blais; P Cheema; C Couture; R Juergens; S Kamel-Reid; M-S Tsao; P Wheatley-Price; Z Xu; D N Ionescu Journal: Curr Oncol Date: 2018-02-28 Impact factor: 3.677